Hi-Q’s research delves into the comprehensive exploration of Oligo Fucoidan and Fucoxanthin in maintaining liver health, their potential role in non-alcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC). Liver health is paramount to overall well-being, and NAFLD, as a prevalent type of liver disease, exhibits an escalating global prevalence. Oligo Fucoidan and Fucoxanthin have been proven to possess antioxidative, anti-inflammatory, and anticancer properties. These constituents play pivotal roles in liver health by ameliorating lipid accumulation and liver damage associated with NAFLD. Additionally, through their modulation of lipid metabolism and immune response, they may indirectly influence HCC development.
Potential Benefits of Oligo Fucoidan and Fucoxanthin in Liver Health
- Exert liver protective effect
- Decrease ALT, CAP, liver stiffness of Non-alcoholic Fatty Liver Disease (NAFLD) patient (Double-blind, placebo-controlled clinical trial)
Hi-Q’s Publications in Liver Health Research
|Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing lncRNA LINC00261 Overexpression
|Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis
|Low Molecular Weight Fucoidan Inhibits Hepatocarcinogenesis and Nonalcoholic Fatty Liver Disease in Zebrafish via ASGR/STAT3/HNF4A Signaling
|Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in a Zebrafish Model
|Protective Effect of Low‐Molecular‐Weight Fucoidan on Radiation‐Induced Fibrosis Through TGF‐β1/Smad Pathway‐Mediated Inhibition of Collagen I Accumulation
|Radioprotective Effect of Self-Assembled Low Molecular Weight Fucoidan–Chitosan Nanoparticles.
|The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase.
|The Anti-Tumor Activity of Brown Seaweed Oligo-Fucoidan via lncRNA Expression Modulation in HepG2 Cells
|Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells